Anthem Q3 top line up 16%; maintains non-GAAP EPS outlook

• Anthem (NYSE:ANTM) Q3 results:
• Revenues: $30.65B (+15.9%) vs. consensus of $29.88B; Commercial & Specialty Business: $9,326M (+0.5%); Government Business: $18,101M (+13.5%); IngenioRx: $5,582M (+190.4%).
• Net Income: $222M (-81.2%); EPS: $0.87 (-80.9%); non-GAAP Net Income: $1,068M (-15.7%); non-GAAP EPS: $4.20 (-13.8%) vs. consensus of $4.18.
• CF Ops: $6,875M (+45.23%).
• Total Medical Membership: 42.6M (+4.0%); Self-Funded Medical Membership: 25.6M (+1.0%); Fully-Insured Medical Membership: 16.9M (+8.8%).
• Benefit Expense Ratio: 86.8%, a decrease of 40 bps from 87.2% in Q2 2020.
• During 3Q 2020, the company paid a quarterly dividend of $0.95 per share, representing a distribution of cash totaling $238M, and declared 4Q dividend of $0.95 per share, payable on December 22 to shareholders of record at the close of business on December 7.
• 2020 Guidance: GAAP EPS: >$17.87 from >$20.91; Non-GAAP EPS: >$22.30 (unch).
• https://seekingalpha.com/news/3627102-anthem-q3-top-line-up-16-maintains-non-gaap-eps-outlook